A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

Completed · Phase 3 · Has a placebo group

Conditions studied: Dermatitis Atopic

In brief

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600\] (ESTUARY).

Key facts

Study ID

NCT06130566

Run by

Sanofi

People needed

601

Starts

2023-11-08

Expected to finish

2025-11-13

Last updated by the study team

2026-07-22

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must be 12 years of age (when signing informed consent form)
• Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)
• Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, and/or inadequate response to systemic therapies (within 12 months before screening)
• v-IGA-AD of 3 or 4 at baseline visit
• EASI score of 16 or higher at baseline
• AD involvement of 10% or more of BSA at baseline
• Weekly average of daily PP-NRS of ≥ 4 at baseline visit.
• Able and willing to comply with requested study visits and procedures
• Body weight ≥25 kg

You may not qualify if…

• Skin co-morbidity that would adversely affect the ability to undertake AD assessments
• Known history of or suspected significant current immunosuppression
• Any malignancies or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured >5 years prior to baseline)
• History of solid organ or stem cell transplant
• Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline (1 week in the event of superficial skin infections)
• Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit
• Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
• Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
• In the Investigator's opinion, any clinically significant laboratory results or protocol specified laboratory abnormalities at screening
• History of hypersensitivity or allergy to any of the excipients or investigational medicinal product (IMP)
• The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial

Where it is running

• MedPharmics - Covington- Site Number : 8401137 — Covington, Louisiana, United States
• MedPharmics - Lafeyette- Site Number : 8401152 — Lafayette, Louisiana, United States
• Massachusetts General Hospital- Site Number : 8401192 — Boston, Massachusetts, United States
• Metro Boston Clinical Partners- Site Number : 8401128 — Needham, Massachusetts, United States
• Revival Research - Doral- Site Number : 8401012 — Dearborn, Michigan, United States
• Henry Ford Hospital- Site Number : 8401044 — Detroit, Michigan, United States
• SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058 — Ridgeland, Mississippi, United States
• MediSearch Clinical Trials- Site Number : 8401140 — Saint Joseph, Missouri, United States
• Somnos Clinical Research- Site Number : 8401203 — Lincoln, Nebraska, United States
• Universal Dermatology- Site Number : 8401224 — Fairport, New York, United States
• Sadick Research Group - New York - Park Avenue- Site Number : 8401050 — New York, New York, United States
• CHEAR Center- Site Number : 8401123 — The Bronx, New York, United States
• Encore Medical Research- Site Number : 8401030 — Hollywood, Florida, United States
• Florida International Research Center- Site Number : 8401091 — Miami, Florida, United States
• Miami Dermatology and Laser Research- Site Number : 8401086 — Miami, Florida, United States
• Clinical Neuroscience Solutions - Orlando - South Delaney Avenue- Site Number : 8401035 — Orlando, Florida, United States
• Cleaver Medical Group Dermatology- Site Number : 8401139 — Cumming, Georgia, United States
• Skin Care Physicians of Georgia - Macon- Site Number : 8401034 — Macon, Georgia, United States
• Javara Research - Thomasville- Site Number : 8401189 — Thomasville, Georgia, United States
• Rophe Adult & Pediatric Medicine- Site Number : 8401289 — Union City, Georgia, United States
• Investigational Site Number : 2760009 — Bad Bentheim, Germany
• Investigational Site Number : 2760014 — Buxtehude, Germany
• Investigational Site Number : 2760017 — Hamburg, Germany
• Investigational Site Number : 2762208 — Kiel, Germany
• Skin Sciences- Site Number : 8401039 — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.